AMPA receptor modulator-12
AMPA receptor modulator-12 is an orally acrive AMPA receptor positive allosteric modulator. AMPA receptor modulator-12 also exhibits moderate binding affinity for the human dopamine transporter with a Kd of 1.57 μM. AMPA receptor modulator-12 enhances AMPA receptor-mediated ion currents, delays channel deactivation. AMPA receptor modulator-12 prolongs sleep latency, reduces sleep duration, extends forced swimming time, improves rotarod endurance, and alleviates acute sleep deprivation-related behavioral deficits. AMPA receptor modulator-12 does not increase spontaneous locomotion. AMPA receptor modulator-12 can be used for the research of narcolepsy and fatigue-related conditions.
For research use only. We do not sell to patients.
- Formula: C25H24F2N2O3S
- Molecular Weight:470.53
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All iGluR Isoforms
More
Biological Activity
|
AMPA Receptor |
AMPA receptor modulator-12 (Compound B1) (10-9-10-3 M; 20 min) exhibits moderate binding affinity for the human dopamine transporter with a Kd of 1.57 μM[1].
AMPA receptor modulator-12 (50 μM-1 mM) concentration-dependently enhancing glutamate-induced peak currents and delaying channel deactivation in HEK293T cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
AMPA receptor modulator-12 (0.2 mmol/kg; i.g.; daily; 5 days) in a pentobarbital-induced sleep mouse model, significantly prolonging sleep latency, reducing sleep onset rate, and shortening sleep duration[1].
AMPA receptor modulator-12 (0.2 mmol/kg; i.g.; daily; 5 days) exhibits significant anti-fatigue activity in mice, prolonging weight-loaded forced swimming time and rotarod endurance and reduces exercise-induced accumulation of fatigue-related metabolic waste products[1].
AMPA receptor modulator-12 (0.2 mmol/kg; p.o.; at 24, 48, and 72 hours during sleep deprivation) effectively reverses behavioral deficits induced by 72 hours of acute sleep deprivation in mice, restoring locomotor and exploratory activity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Pentobarbital-induced sleep mouse model (male, 3-8 weeks old, 18-22 g)[1]
-
Dosage:0.2 mmol/kg
-
Administration:I.g.,; daily; 5 days
-
Result:Prolonged sleep latency significantly compared to the blank control group.
Reduced sleep onset rate to 60%.
Shortened sleep duration markedly compared to both the blank control group and the positive control modafinil group.
Did not cause significant changes in spontaneous locomotor activity relative to the blank control group.
-
Animal Model:Acute sleep deprivation-induced behavioral deficit in mice (male, 3-8 weeks old, 18-22 g)[1]
-
Dosage:0.2 mmol/kg
-
Administration:I.g.; at 24, 48, and 72 hours during sleep deprivation
-
Result:Increased total movement time significantly, total travel distance significantly, and center zone movement significantly compared to the sleep-deprived model group, reversing deficits in spontaneous activity and exploratory behavior.
Prevented sleep deprivation-induced hippocampal neuronal necrosis in the CA1 and DG regions, maintaining abundant, regularly aligned, compact neurons without evident degeneration or necrosis, similar to the non-deprived blank control group.
Chemical Information
-
Molecular Weight 470.53
-
Formula C25H24F2N2O3S
-
SMILES
O=C(NCCCNC(CS(C(C1=CC=C(F)C=C1)C2=CC=C(F)C=C2)=O)=O)C3=CC=CC=C3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
- AMPA receptor modulator-12
- AMPA receptor modulator12
- AMPA receptor modulator 12
- iGluR
- Dopamine Transporter
- GluA1/GluA2
- HEK293T cells
- glutamate
- hippocampal neuronal damage
- dopamine transporter
- AMPA receptor
- fatigue-related conditions
- narcolepsy
- acute sleep deprivation
- pentobarbital-induced sleep mouse model
- Inhibitor
- inhibitor
- inhibit